Topic:

R&D

Latest Headlines

Latest Headlines

Upbeat review of PhII DMD trial earns Prosensa a big boost to shares

After the markets closed last night, Prosensa issued an upbeat self-assessment of its 48-week extension data from a Phase II study of its lead drug drisapersen for Duchenne muscular dystrophy.

Intercept's lead drug boasts success in PhIII after worrisome side-effects disclosure

Intercept Pharmaceuticals delivered a bad news-good news punch over the weekend about its lead drug.

Amgen goes 6-for-6 in Phase III, leading the race for a new cardio blockbuster

Amgen's promising cardio drug aced its 6th late-stage study, the company said, beating out statins in patients with a cholesterol-boosting genetic disorder and widening the drugmaker's lead in a potentially lucrative new field.

PPD lands a federal bioterror deal worth up to $100M

PPD has signed a contract with the U.S. government's Biomedical Advanced Research and Development Authority, agreeing to design and conduct clinical trials for products that protect against bioterrorism and other public health emergencies.

Statins and muscle aches are unrelated

So is Lipitor or Crestor causing you to have muscle aches? The answer is no, according to a new meta-analysis of the side effects of the cholesterol-lowering drugs.

GSK touts Anoro results as it preps for generic attacks on $8B-seller Advair

With aging top dog Advair losing ground to generic and branded competitors alike, GlaxoSmithKline is grooming a lineup of respiratory up-and-comers to step in with their own blockbuster sales. And new study results comparing Advair with not-yet-launched Anoro Ellipta could help the fledgling COPD treatment do just that.

Waters Corp. will help develop a blood-based biomarker test to predict the risk of premature birth

Waters Corp. inked a research partnership deal with an Irish research facility targeted toward developing a blood-based biomarker test that can predict whether a fetus is at high risk for premature birth.

With $25M in the bank, French startup sets its sights on sepsis

France's Inotrem is working up a novel approach to the global scourge of sepsis, and now, thanks to some high-profile investors, the biotech has $25 million to take its immunotherapy from the benchtop to the clinic.

Another Glaxo respiratory drug sees regulatory filings in its future

The British pharma giant says it's nailed the primary endpoint in a Phase III study of its injectable candidate mepolizumab, which will help set the severe eosinophilic asthma treatment up for its first regulatory filings.

Analysts see $1.5B boost for Pfizer on 'better than expected' Prevnar 13 data

Pfizer's Prevnar 13 vaccine slashed the number of pneumonia cases in older adults, according to details from a new study that could add up to $1 billion to its global sales.